Navigation Links
MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
Date:4/7/2008

ines. The company applies its proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates, Unit Dose Budesonide and MAP0004, in late stage development for the potential treatment of pediatric asthma and migraine respectively. MAP Pharmaceuticals' pipeline also includes a drug candidate in early clinical development for the treatment of asthma and chronic obstructive pulmonary disease.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Forward-Looking Statements

In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to the further development of MAP0005 and the potential application of MAP Pharmaceuticals' technologies to additional product candidates. Actual results may differ materially from current expectations based on risks and uncertainties affecting the Company's business, including, without limitation, risks and uncertainties relating to the development and commercialization of product candidates incorporating MAP Pharmaceuticals' technologies. The reader is cautioned not to unduly rely on the forward- looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Annual Report on Form 10K, filed with the SEC on March 20, 2008, available at http://edgar.sec.gov.


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
2. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
3. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
4. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
5. ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
6. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
7. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
8. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
9. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
10. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
11. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... RIDGE, N.J. , Oct. 22, 2014 /PRNewswire/ ... (RMANJ), a world-renowned leader in the field of ... rapid approach to embryonic screening. The research abstract, ... Society for Reproductive Medicine (ASRM) meeting in ... screening (CCS) and single gene defect (SGD) pre-implantation ...
(Date:10/22/2014)... ATLANTA , Oct. 22, 2014  CryoLife, Inc. ... and tissue processing company focused on cardiac and vascular ... , President and Chief Executive Officer, has been elected ... 2014. Steven G. Anderson , Executive ... Pat has proven to be an excellent leader who ...
(Date:10/22/2014)... Calif., Oct. 21, 2014 Abaxis, Inc. (NasdaqGS: ... point-of-care blood analysis systems, today reported financial results for ... Second quarter overview: , Revenues of $53.9 ... , Diluted EPS of $0.24, up 33% over last ... Service revenues from Abaxis Veterinary Reference Laboratories (AVRL) of ...
Breaking Medicine Technology:New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14
... , PHOENIX , Feb. ... selected SCAN Health Plan Arizona as their Medicare Advantage Plan (MAPD) ... to join SCAN until March 31, 2010 . , ... is affiliated with more than 6,800 physician locations as well as ...
... , SAN DIEGO , Feb. 9 ... manufacturer of precision intravascular therapy guidance tools designed to enhance ... announced today that it has received 510(k) clearance from the ... Eye® Platinum digital IVUS catheter in the United States ...
Cached Medicine Technology:SCAN Health Plan Arizona Exceeds Expectations as Local Seniors Select Medicare Advantage Coverage 2SCAN Health Plan Arizona Exceeds Expectations as Local Seniors Select Medicare Advantage Coverage 3Volcano Receives FDA Clearance to Market the Eagle Eye(R) Platinum Digital IVUS Catheter 2Volcano Receives FDA Clearance to Market the Eagle Eye(R) Platinum Digital IVUS Catheter 3Volcano Receives FDA Clearance to Market the Eagle Eye(R) Platinum Digital IVUS Catheter 4
(Date:10/25/2014)... (PRWEB) October 25, 2014 QueenBeeTickets.com has ... a great selection at affordable prices. Bob Seger & ... Huntington Center and Nationwide Arena are going on sale ... Click Here to browse the selection of ... at QueenBeeTickets.com. , The famous singer is touring North ...
(Date:10/25/2014)... FRIDAY, Oct. 24, 2014 (HealthDay News) -- Interrupting blood supply ... help reduce the risks associated with the surgery, according to ... to stop the blood supply to the heart to be ... blood, the heart will reduce its ability to produce energy ... blood flow to another large muscle, such as an arm ...
(Date:10/25/2014)... Oct. 23, 2014 (HealthDay News) -- Current osteoporosis ... younger postmenopausal women at risk for osteoporosis-related fractures, ... to prevent fractures, we need tools that help ... injuries so that we can target these at-risk ... Crandall, professor of medicine in the division of ...
(Date:10/22/2014)... On October 22, CBS will air an episode ... fictional and real. The Charles E Holman Morgellons ... advocacy and philanthropy in the battle against Morgellons Disease, ... impart truth and clarity about this misunderstood and routinely ... about Morgellons Disease (MD) and most people ...
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- The ... passengers arriving from Ebola-affected nations of West Africa ... screen them for infection with the virus. ... Jeh Johnson noted that 94 percent of air ... land at one of these five airports -- ...
Breaking Medicine News(10 mins):Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3
... the secure,remote service and support company today announced ... MCK ), has selected,the Axeda(R) ServiceLink solution ... which ensure safety and accuracy throughout the,medication use ... Axeda(R) Software Management,application will be used to remotely ...
... mission-critical outsourcing to Brooke Army Medical Center, ... SINT ), an information technology and network ... a new competitive task order under,the US Army,s ... Personnel Service and Support to provide,services to Brooke ...
... CHARLES TOWN, W.Va., Oct. 16 ReBuilder,Medical Technologies, ... agreed upon a Joint Venture with UFFE Medical, ... ReBuilder Medical,s unique home treatment for,the skin disease ... sometimes hundreds of pimple-like lesions that can take ...
... has been named one of 10 new centers in ... make critical treatment decisions about therapeutic products and interventions. ... for Healthcare Research and Quality,s Center for Education and ... and test systems to optimize drug choice, monitoring and ...
... Today, the International Association for the Study of Pain (IASP) ... to draw attention to the significant impact of chronic pain ... Lack of awareness of pain issues affecting women and ... of millions of women. , Chronic pain affects a ...
... Discovery could lead to new therapies , TUESDAY, Oct. 16 ... cancer has been identified. The finding about the Dmp1 ... at the cellular level to cause lung cancer. , The ... of human non-small-cell lung cancers and found that the ...
Cached Medicine News:Health News:Axeda Selected for Remote Monitoring and Service of Automation Technologies 2Health News:SI International Awarded $4 Million Army HRsolutions Task Order 2Health News:SI International Awarded $4 Million Army HRsolutions Task Order 3Health News:ReBuilder Medical Technologies, Inc. Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical, LTD. Expected 10% Sales Increase. 2Health News:ReBuilder Medical Technologies, Inc. Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical, LTD. Expected 10% Sales Increase. 3Health News:New UIC center to study drug choices, safety 2Health News:IASP declares the Global Year Against Pain in Women 2Health News:IASP declares the Global Year Against Pain in Women 3Health News:Researchers ID New Gene Linked to Lung Cancer 2
... Ureteral Stents have all the advantages ... addition, a unique 360 degree kidney ... placement in the renal pelvis or ... remarkably comfortable stent, ideal for use ...
All the advantages of Dr. Roy P. Finney's classic stent design with an open tip....
This EIA microplate opens new perspectives in the direct detection of Chlamydia. The choice of microplate immunoenzymatic technology and the use of a monoclonal antibody result in a combination of c...
Inquire...
Medicine Products: